Refine by
Drug Stability Articles & Analysis: Older
23 news found
“Whether customers are trying to develop a new drug or seeking to improve the release characteristics of an existing drug, our lyophilization and flash-release technology are there to help,” said Protheragen-ING’s Chief Scientist. Over the past decade, the use of the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanoderived ...
Among the 15 approved ADCs globally, notable therapies like Trodelvy and Zynlonta utilize PEG linkers to enhance drug stability and targeting. The benefits of incorporating PEGs into ADC formulations are significant, including improved solubility, prolonged circulation time, and reduced immunogenicity, all of which contribute to more effective cancer treatments. ...
This strategic move is aimed at addressing the rising global demand for Lipid Nanoparticles (LNPs), which are vital for nucleic acid drug delivery, especially in mRNA-based therapies and vaccines. Lipid Nanoparticles have become a groundbreaking delivery mechanism within the biopharmaceutical sector. ...
The Y-Shape PEG NHS is particularly valuable in drug development and therapeutic protein formulation. It enhances drug stability, prolongs circulation time, and reduces immunogenicity, making it an essential tool for creating more effective and safer biologic drugs. ...
CD Formulation is making waves in the pharmaceutical industry with its innovative drug delivery technologies. With a focus on sustained and controlled release formulations, as well as liquid, semi-solid, injectable, and nanoformulations, CD Formulation is at the forefront of the industry's efforts to enhance drug efficacy. ...
CD Formulation, a leading innovator in drug delivery technologies, has recently introduced a series of groundbreaking microneedle patch innovations that promise to revolutionize the way drugs are administered. ...
STEMart, a US-based provider of comprehensive services for all phases of medical device development, announced the launch of its new Force Degradation Services to help pharmaceutical and medical device companies evaluate the stability of their drug candidates and finished products under a variety of stress conditions, ensuring their safety and efficacy throughout ...
BySTEMart
CD Formulation's cutting-edge research and development team has successfully created micro-reservoir systems that offer precise drug release kinetics. By manipulating key factors such as reservoir size, drug loading, and polymer selection, the team has achieved remarkable control over drug release rates. ...
In the field of pharmaceutical formulation, stability analysis is a critical aspect that ensures the safety and efficacy of drugs throughout their shelf life. ...
These advanced systems offer unique benefits, including enhanced drug stability, sustained release, and targeted delivery. However, the successful formulation and optimization of these delivery systems pose significant challenges that require expertise and advanced technologies. ...
These new technologies, including drug half-life extension technologies, injection site drug reservoir technologies, and drug physicochemical enhancement technologies, offer new possibilities in the treatment of many chronic diseases. ...
The ARAI autoinjector has been developed by Aktiv with the support of BARDA and the Department of Defense (DoD) as a next generation autoinjector platform to address the shortfalls of previous autoinjectors, by improving usability, reliability, robustness, and drug stability. ARAI is a versatile platform that can deliver up to 5 ml dose volumes, perform ...
Broomfield Colorado 6/16/2022. Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in ...
Fully aware of this, CD Formulation, a New York-based CRO company reputed for high-quality drug pre-formulation services, announced earlier this month to have launched long-term accelerated shelf-life testing for drug developers and pharmaceutical companies worldwide. ...
” To date, Aktiv has met several critical milestones in the TXA autoinjector program, including development of a proprietary formulation, performing stability studies, and completing a number of promising preclinical studies. ...
To ensure the safety and efficacy of the drug product, chemical stability is of paramount importance. Earlier this month, CD Formulation announced its decision to launch forced degradation studies to help researchers find ways to promote drug stability. The forced degradation study, also known as stress testing, is carried out to ...
Pharmaceutical excipients play magic roles to achieve better drug delivery and adoption. Many challenges can be resolved with the optimal choice of excipients. ...
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. The company has recently announced Protein Drug Modification Analysis service to help researchers determine the modification type, modification site, and modification structure of protein ...
Recognized as a CRO for pharmaceutical formulation, CD Formulation recently announces to have optimized its stability analysis service, providing solid-state stability analysis, solution-state stability analysis, APIs-excipients compatibility analysis for researchers devoted to drug formulation research. ...
Under this contract, Aktiv Pharma Group will advance a pralidoxime chloride (2-PAM) auto-injector toward U.S. Food and Drug Administration (FDA) approval. Subsequently, in 2018, BARDA awarded Aktiv Pharma Group a $15.5 million contract to develop a Good Manufacturing Practice (GMP) manufacturing line for the ARAI autoinjector platform, which was completed in December 2019. 2-PAM ...